Immunotherapy in Relapsed/Refractory Multiple Myeloma: Nursing Considerations

Charise L. Gleason, MSN, NP-C


September 29, 2022

The emergence of a wider range of treatment options in multiple myeloma, including newer immunotherapies, has improved outcomes, notably for patients with relapsed or refractory disease.

Nurses play a pivotal role in the successful use of these therapies by providing in-depth patient education about methods of administration and wide-ranging side effects. Considering the multiple options now available, and their complexity and varied safety profiles, it is important for nurses to understand the newer immunotherapies to prepare patients adequately for shared decision-making.

Oncology nurse practitioner Charise Gleason from Emory Winship Cancer Institute discusses the latest advances in immunotherapy for relapsed/refractory multiple myeloma patients, ways in which these therapies affect nursing care, and how nurses can prepare to incorporate them smoothly into clinical practice.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.